What Clinicians Need to Know About Oral Antivirals for COVID-19: An Expert Q&A
In this Q&A, Erica Johnson, MD, provides insight into the new oral antiviral medications that may soon be approved for the treatment of COVID-19.
Features Drug
Q&A: Monoclonal Antibodies for COVID-19
The IDSA recommends that antibody therapy should be administered to patients with mild to moderate COVID-19 at high risk for progression to severe disease.
Expert Perspective: The Opioid Crisis and COVID-19
To learn more about the overlapping crises of the opioid epidemic and the COVID-19 pandemic, Psychiatry Advisor interviewed pain specialist Paul J. Christo, MD, MBA, the Director of the Multidisciplinary Pain Fellowship Program at Johns Hopkins Hospital in Baltimore, Maryland.
Pharmacogenetics in Antidepressant Selection for Major Depressive Disorder
Presently, clinicians should be urged to view genetics as an additional tool in choosing prescriptions for MDD, as opposed to a replacement for complete clinical evaluation.
Helping Patients Quit Smoking: A Road Map for Clinicians
Successful smoking cessation involves a 2-pronged approach, since there are 2 components to smoking – physiological and behavioral, according to Nervana Elkhadragy, PharmD, MS, TTS, of Purdue University, College of Pharmacy, Indianapolis.
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
AAN Issues Guideline Update for Immunization in Patients With MS
AAN has issued a practice guideline update for vaccine-preventable infections and immunizations for individuals with multiple sclerosis (MS). A subcommittee of the AAN — tasked with developing, disseminating and implementing these guidelines — found improvements and additions to the recommendations previously issued in 2002.
Important Information for Your Patients Considering SLIT-Tablet Therapy for HDM-Induced Allergic Rhinitis
This article is sponsored by ALK, Inc. The house dust mite (HDM),and specificallyHDM speciesDermatophagoides farina and Dermatophagoides pteronyssinus, are common causes of allergic rhinitis (AR).1 In 2013, approximately 84% of households in the United States reported detectable levels of dust mite allergens.2 Commonly used therapeutic approaches for the management of HDM-induced AR include HDM avoidance, pharmacotherapy, and…
The Management of House Dust Mite-Induced Allergic Rhinitis
In 2013, approximately 84% of households in the United States reported detectable levels of dust mite allergens.
How Often Does the FDA Disagree With Its Advisory Committees’ Recommendations?
According to the findings of a recent review, the Food and Drug Administration rarely disagrees with recommendations made by its advisory committees.
